RedHill Biopharma Ltd., an Israeli biopharmaceutical company, filed a Post-Effective Amendment No. 1 to Form F-1 with the SEC on April 18, 2024. This amendment pertains to the registration of 10,600,000 American Depositary Shares (ADSs), representing 4,240,000,000 ordinary shares. The ADSs are issuable upon the exercise of previously issued warrants as part of a concurrent private placement during a registered direct offering in January 2024. The warrants, exercisable immediately upon issuance at a price of $1.00 per ADS, will expire five years from the date of issuance. The registration statement was initially filed on February 9, 2024, and declared effective by the SEC on February 15, 2024. The amendment includes the incorporation of the company's Form 20-F for the year ended December 31, 2023, filed on April 8, 2024, and updates selling shareholder...Show More

RedHill Biopharma Ltd., an Israeli biopharmaceutical company, filed a Post-Effective Amendment No. 1 to Form F-1 with the SEC on April 18, 2024. This amendment pertains to the registration of 10,600,000 American Depositary Shares (ADSs), representing 4,240,000,000 ordinary shares. The ADSs are issuable upon the exercise of previously issued warrants as part of a concurrent private placement during a registered direct offering in January 2024. The warrants, exercisable immediately upon issuance at a price of $1.00 per ADS, will expire five years from the date of issuance. The registration statement was initially filed on February 9, 2024, and declared effective by the SEC on February 15, 2024. The amendment includes the incorporation of the company's Form 20-F for the year ended December 31, 2023, filed on April 8, 2024, and updates selling shareholder information. The amendment is part of the company's undertaking to update and supplement information contained in the original registration statement. No additional securities are being registered under this amendment, and it concerns only the offer and sale of ADSs issuable upon the exercise of the warrants that remain unexercised. All filing fees associated with the registration of these securities were previously paid with the initial filing of the Registration Statement.